Written by: Jeff Engle, PharmD, MS
Download Here

This PQI will discuss effective management of adverse effects of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma and discuss data supporting the sequencing of patients to second-line therapy with regorafenib for increased survival benefit.

Continue reading Sorafenib for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib

Read More

Written by: Tammy McClellan, PharmD
Download Here

The purpose of this PQI is to expand on therapy management of ibrutinib (Imbruvica) when used in combination with obinutuzumab (Gazyva).

Continue reading Ibrutinib expansion with Obinutuzumab

Read More

Written by: Natasha Heimbigner, PharmD, Summit Cancer Centers
Download Here

Proper prevention and management of immunotherapy related rash is an important intervention for the patient’s quality of life and continuation of therapy. Continue reading Managing Immunotherapy Treatment Related Rash

Read More

Written by: Jody Agena, PharmD, Virginia Cancer Specialists
Download Here

Understand how to identify eligible patients and manage adverse effects of Regorafenib (Stivarga) treatment in Hepatocellular Carcinoma. Continue reading Regorafenib in the treatment of Hepatocellular Carcinoma

Read More